CGTLive’s Weekly Rewind – November 24, 2023

CGTLive’s Weekly Rewind – November 24, 2023

Welcome to CGTLive™’s Weekly Rewind! We’ve compiled 5 highlights from this week’s coverage of advances in gene and cell therapies, including FDA actions, notable research, and interviews with experts across the field. This week’s coverage includes some highlights from the recent American Heart Association meeting.

1. Safety Monitoring Critical as Cardiology Wades Into Gene Therapy for Hypertrophic Cardiomyopathy

Milind Desai, MD, MBA, the director of the Hypertrophic Cardiomyopathy Center and the vice chair of the Heart Vascular Thoracic Institute at the Cleveland Clinic, discussed the design of Tenaya Therapeutics’ clinical trial evaluating TN-201.

2. Roger Hajjar, MD, on Gene Therapy as a Novel Precision Medicine Modality in Cardiology

The director of the Mass General Brigham Gene and Cell Therapy Institute shared his main message for cardiologists at the American Heart Association’s Scientific Sessions 2023.

3. Patients With Congestive Heart Failure Show Clinically Meaningful Improvements After Gene Therapy

AskBio presented data from a phase 1/2 trial of AB-1002 gene therapy at the AHA Scientific Sessions 2023 meeting.

4. J. Andrew Livingston, MD, on Starting the Shift Toward Targeted Therapies in Sarcoma

The associate professor at MD Anderson Cancer Center discussed his future outlook and goals for the field of sarcoma.

5. Lepodisiran Reduces Lipoprotein(a) Levels Safely in Phase 1 Data, Paving Way for Further Study

Eli Lilly’s small interfering RNA therapy showed significant serum reductions with a single dose while remaining well-tolerated. A larger phase 2 study is currently ongoing.